Characterization of the novel HLA-B*56:76 allele by sequencing-based typing.

HLA-B*56:76 human leukocyte antigen novel allele sequencing-based typing

Journal

HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570

Informations de publication

Date de publication:
07 2021
Historique:
received: 17 02 2021
accepted: 19 02 2021
pubmed: 25 2 2021
medline: 8 7 2021
entrez: 24 2 2021
Statut: ppublish

Résumé

HLA-B*56:76 differs from HLA-B*56:01:01:03 by a single nucleotide change at position 205 in exon 2.

Identifiants

pubmed: 33624425
doi: 10.1111/tan.14237
doi:

Substances chimiques

HLA-B Antigens 0
HLA-B56 antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

66-67

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE. IPD-IMGT/HLA database. Nucleic Acids Res. 2020;48(D1):D948-D955. https://doi.org/10.1093/nar/gkz950.
Cargou M, Ralazamahaleo M, Blouin L, et al. Evaluation of the AllType kit for HLA typing using the ion torrent S5 XL platform. HLA. 2020;95(1):30-39. https://doi.org/10.1111/tan.13708.
McGuffin LJ, Bryson K, Jones DT. The PSIPRED protein structure prediction server. Bioinformatics. 2000;16(4):404-405. https://doi.org/10.1093/bioinformatics/16.4.404.
Menezes Teles E, Oliveira D, Melo Santos de Serpa Brandao R, et al. pHLA3D: an online database of predicted three-dimensional structures of HLA molecules. Hum Immunol. 2019;80(10):834-841. https://doi.org/10.1016/j.humimm.2019.06.009.
Ponomarenko J, Bui H-H, Li W, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinform. 2008;9:514. https://doi.org/10.1186/1471-2105-9-514.
Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75(4):291-455. https://doi.org/10.1111/j.1399-0039.2010.01466.x.

Auteurs

Lucie Blandin (L)

Histocompatibility and Immunogenetics laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Jonathan Visentin (J)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.
University of Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France.

Gwendaline Guidicelli (G)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.
University of Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France.

Paul Rouzaire (P)

Histocompatibility and Immunogenetics laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
Clermont-Auvergne University, Clermont-Ferrand, France.

Richard Lemal (R)

Histocompatibility and Immunogenetics laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
Clermont-Auvergne University, Clermont-Ferrand, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH